

Rolf A Brekken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8475823/publications.pdf>

Version: 2024-02-01

238
papers

19,557
citations

10956

71
h-index

13338

130
g-index

254
all docs

254
docs citations

254
times ranked

28166
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MYC</i> Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 542-561.	7.7	35
2	AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 38-47.	1.9	9
3	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	3.3	29
4	Are TEMs Canceled? Questioning the Functional Relevance of Tie2-Expressing Macrophages. <i>Cancer Research</i> , 2022, 82, 1172-1173.	0.4	1
5	CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target. <i>Cancers</i> , 2022, 14, 86.	1.7	14
6	Direct and indirect regulation of the tumor immune microenvironment by VEGF. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1269-1286.	1.5	28
7	Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. <i>Cancer Cell</i> , 2022, 40, 656-673.e7.	7.7	155
8	Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2022, 40, 9081-9081.	0.8	3
9	SPARC is a key mediator of TGF β -induced renal cancer metastasis. <i>Journal of Cellular Physiology</i> , 2021, 236, 1926-1938.	2.0	29
10	High-dimensional immunotyping of tumors grown in obese and non-obese mice. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	7
11	Hemolysis-associated phosphatidylserine exposure promotes polyclonal plasmablast differentiation. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	12
12	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. <i>Blood</i> , 2021, 137, 1839-1842.	0.6	2
13	AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1412-1421.	1.5	16
14	Perspectives on Hypoxia Signaling in Tumor Stroma. <i>Cancers</i> , 2021, 13, 3070.	1.7	18
15	Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-stimulated T Cell IFN- γ and TNF- α Production. <i>Journal of Immunology</i> , 2021, 207, 436-448.	0.4	1
16	Neuropathological Effects of Chemotherapeutic Drugs. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3038-3048.	1.7	10
17	DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. <i>JCI Insight</i> , 2021, 6, .	2.3	60
18	Location matters: Profiling diffuse type gastric cancer at the single cell level. <i>Clinical Cancer Research</i> , 2021, 27, clincanres.2935.2021.	3.2	0

#	ARTICLE	IF	CITATIONS
19	VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. JCI Insight, 2021, 6, .	2.3	22
20	919â€¦Tegavivint reduces the immunosuppressive macrophage phenotype in a preclinical co-culture model of the non-small cell lung cancer tumor microenvironment. , 2021, 9, A964-A964.		0
21	The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis. Cancers, 2021, 13, 6206.	1.7	63
22	Targeting TAM to Tame Pancreatic Cancer. Targeted Oncology, 2020, 15, 579-588.	1.7	4
23	AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. IScience, 2020, 23, 101649.	1.9	20
24	¹⁸ Np63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leaderâ€“Follower Relationship That Drives Collective Invasion. Cancer Research, 2020, 80, 3933-3944.	0.4	13
25	Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Scientific Reports, 2020, 10, 20662.	1.6	3
26	Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment. Cancers, 2020, 12, 2652.	1.7	71
27	Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. Cancer Prevention Research, 2020, 13, 911-922.	0.7	20
28	Concentration-dependent Early Antivasular and Antitumor Effects of Itraconazole in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 6017-6027.	3.2	16
29	Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 487-505.	8.2	458
30	Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. American Journal of Physiology - Cell Physiology, 2020, 319, C233-C243.	2.1	23
31	TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy. Cell Communication and Signaling, 2020, 18, 29.	2.7	23
32	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology, 2020, 15, 973-999.	0.5	66
33	Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. Gastric Cancer, 2020, 23, 824-836.	2.7	25
34	Loss of BAP1 Leads to More YAPing in Pancreatic Cancer. Cancer Research, 2020, 80, 1624-1625.	0.4	5
35	Beyond Stiffness. American Journal of Pathology, 2020, 190, 1622-1624.	1.9	3
36	Procoagulant Activity of Skeletal Muscle Myosin Is Not Caused By Contaminating Phosphatidylserine-Vesicles. Blood, 2020, 136, 20-21.	0.6	0

#	ARTICLE	IF	CITATIONS
37	2-Amino-2,3-dihydro-1 <i>H</i> -indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7431-7444.	2.9	43
38	Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 1049.	1.3	24
39	Targeting $TGF\beta 2$ mutant tumors exposes vulnerabilities to stromal $TGF\beta 2$ blockade in pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10515.	3.3	56
40	<p>APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice<p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 249-259.	1.0	7
41	The effect of flow on blood oxygen level dependent (R^{*2}) MRI of orthotopic lung tumors. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 3787-3797.	1.9	11
42	Getting a grip on adhesion: Cadherin switching and collagen signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 118472.	1.9	31
43	Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. <i>Molecular Cancer</i> , 2019, 18, 68.	7.9	169
44	Collagen Signaling in Cancer. , 2019, , 89-108.		2
45	Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. <i>Archives of Biochemistry and Biophysics</i> , 2019, 661, 97-106.	1.4	5
46	The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer. <i>Cancer Research</i> , 2019, 79, 328-330.	0.4	38
47	$\beta 1$ Syntrophin Supports Autophagy Initiation and Protects against Cerulein-Induced Acute Pancreatitis. <i>American Journal of Pathology</i> , 2019, 189, 813-825.	1.9	6
48	Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 348-355.	1.5	14
49	Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Immunology</i> , 2019, 202, 292-299.	0.4	39
50	Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. <i>Cell Death and Differentiation</i> , 2019, 26, 382-393.	5.0	49
51	Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25880-25890.	3.3	47
52	Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	26
53	Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. <i>JCI Insight</i> , 2019, 4, .	2.3	169
54	Human pancreatic cancer cell exosomes, but not human normal cell exosomes, act as an initiator in cell transformation. <i>ELife</i> , 2019, 8, .	2.8	63

#	ARTICLE	IF	CITATIONS
55	Exploration of Nanoparticle-Mediated Photothermal Effect of TMB-H ₂ O ₂ Colorimetric System and Its Application in a Visual Quantitative Photothermal Immunoassay. <i>Analytical Chemistry</i> , 2018, 90, 5930-5937.	3.2	201
56	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 246-255.	0.4	127
57	Assessment of TANK-binding kinase 1 as a therapeutic target in cancer. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 83-90.	1.8	31
58	Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. <i>JCI Insight</i> , 2018, 3, .	2.3	81
59	Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor- β receptor type I inhibitor. <i>Oncotarget</i> , 2018, 9, 6659-6677.	0.8	112
60	Does Axl have potential as a therapeutic target in pancreatic cancer?. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 955-966.	1.5	21
61	Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 1-14.	2.7	34
62	Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction. <i>Molecular Metabolism</i> , 2018, 16, 139-149.	3.0	20
63	Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- <i>a</i>]pyrazin-3-ylethynyl)-4-isopropyl- <i>N</i> -(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7977-7990.	2.9	24
64	Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. <i>Neoplasia</i> , 2018, 20, 826-837.	2.3	40
65	Inhibition of Discoidin Domain Receptor 1 Prevents Stroma-Induced Peritoneal Metastasis in Gastric Carcinoma. <i>Molecular Cancer Research</i> , 2018, 16, 1590-1600.	1.5	38
66	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. <i>Nature Communications</i> , 2017, 8, 14098.	5.8	80
67	Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 662-670.	1.9	17
68	Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 327-332.	1.3	31
69	Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. <i>BMC Cancer</i> , 2017, 17, 87.	1.1	48
70	A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. <i>Oncogene</i> , 2017, 36, 5122-5133.	2.6	79
71	Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies. <i>British Journal of Cancer</i> , 2017, 117, 545-552.	2.9	103
72	From top to bottom: midkine and pleiotrophin as emerging players in immune regulation. <i>Journal of Leukocyte Biology</i> , 2017, 102, 277-286.	1.5	55

#	ARTICLE	IF	CITATIONS
73	Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and β 2AR-Dependent Neo-Angiogenic Switch. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1442-1454.	3.1	57
74	A transistor-like pH nanoprobe for tumour detection and image-guided surgery. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	163
75	Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor. <i>Nature Cell Biology</i> , 2017, 19, 1226-1236.	4.6	38
76	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2473-2485.	1.9	86
77	The Extracellular Matrix of Tumors: A Focus on Fibronectin and Fibulin-5. <i>Biology of Extracellular Matrix</i> , 2017, , 1-15.	0.3	0
78	Extracellular Matrix Induction of Intracellular Reactive Oxygen Species. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 774-784.	2.5	24
79	Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend <i>C. elegans</i> lifespan. <i>Nature Communications</i> , 2017, 8, 2270.	5.8	121
80	Drivers of EMT and Immune Evasion. , 2017, , 221-239.		1
81	Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. <i>PLoS ONE</i> , 2016, 11, e0158757.	1.1	25
82	Effective Rat Lung Tumor Model for Stereotactic Body Radiation Therapy. <i>Radiation Research</i> , 2016, 185, 616-622.	0.7	7
83	Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5911-5916.	2.9	51
84	Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1357-1362.	0.5	32
85	Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 531-540.	1.6	20
86	Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. <i>Annals of Surgical Oncology</i> , 2016, 23, 583-591.	0.7	18
87	Hypoxia and Transforming Growth Factor β 2 Cooperate to Induce Fibulin-5 Expression in Pancreatic Cancer. <i>Journal of Biological Chemistry</i> , 2016, 291, 22244-22252.	1.6	35
88	The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. <i>Science Translational Medicine</i> , 2016, 8, 365ra159.	5.8	42
89	Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. <i>Cell Death and Differentiation</i> , 2016, 23, 962-978.	5.0	506
90	P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. <i>Cell Reports</i> , 2016, 14, 2193-2208.	2.9	58

#	ARTICLE	IF	CITATIONS
91	Matrix control of pancreatic cancer: New insights into fibronectin signaling. <i>Cancer Letters</i> , 2016, 381, 252-258.	3.2	89
92	Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. <i>Oncotarget</i> , 2016, 7, 51569-51580.	0.8	17
93	Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. <i>Oncotarget</i> , 2016, 7, 30678-30690.	0.8	36
94	The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy. <i>Current Drug Targets</i> , 2016, 17, 1747-1754.	1.0	8
95	Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo. , 2015, 56, 7137.		10
96	Stromal TGFÎ²R2 signaling: a gateway to progression for pancreatic cancer. <i>Molecular and Cellular Oncology</i> , 2015, 2, e975606.	0.3	5
97	CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. <i>Cancer Letters</i> , 2015, 359, 335-343.	3.2	82
98	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. <i>Cancer Letters</i> , 2015, 358, 59-66.	3.2	48
99	Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. <i>Cancer Research</i> , 2015, 75, 3699-3705.	0.4	127
100	Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B. <i>Nature Chemical Biology</i> , 2015, 11, 401-408.	3.9	54
101	Unbiased Selection of Peptideâ€“Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells. <i>ACS Chemical Biology</i> , 2015, 10, 2891-2899.	1.6	28
102	A rapid <i>in vivo</i> screen for pancreatic ductal adenocarcinoma therapeutics. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1201-1211.	1.2	14
103	NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by Î²-lapachone. <i>Cell Death and Disease</i> , 2015, 6, e1599-e1599.	2.7	76
104	Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 5058-5069.	0.4	33
105	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. <i>Journal of Clinical Investigation</i> , 2015, 125, 4063-4076.	3.9	79
106	Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 493-503.	1.0	12
107	Role of SPARC in Bone Remodeling and Cancerâ€“Related Bone Metastasis. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 17-26.	1.2	57
108	Neutralizing Murine TGFÎ²R2 Promotes a Differentiated Tumor Cell Phenotype and Inhibits Pancreatic Cancer Metastasis. <i>Cancer Research</i> , 2014, 74, 4996-5007.	0.4	56

#	ARTICLE	IF	CITATIONS
109	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. <i>Molecular Cancer</i> , 2014, 13, 237.	7.9	60
110	Recruitment and retention: factors that affect pericyte migration. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 299-309.	2.4	64
111	Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2014, 74, 1032-1044.	0.4	88
112	Vascular channels formed by subpopulations of PECAM1+ melanoma cells. <i>Nature Communications</i> , 2014, 5, 5200.	5.8	55
113	Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15999-16004.	3.3	50
114	Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis. <i>Cancer Discovery</i> , 2014, 4, 25-26.	7.7	5
115	Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice. <i>Gastroenterology</i> , 2014, 146, 1339-1350.e1.	0.6	196
116	Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. <i>Journal of Clinical Investigation</i> , 2014, 124, 824-834.	3.9	78
117	Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models. <i>Clinical Cancer Research</i> , 2014, 20, B30-B30.	3.2	3
118	Abstract A04: TBK1 as a novel mediator of K-Ras driven pancreatic cancer. , 2014, , .		1
119	Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. <i>Oncotarget</i> , 2014, 5, 9811-9822.	0.8	39
120	Hypoxia Studies with Pimonidazole in vivo. <i>Bio-protocol</i> , 2014, 4, .	0.2	77
121	Abstract B19: Rapid in vivo screen of pancreatic ductal adenocarcinoma therapeutics. , 2014, , .		0
122	27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth. <i>Cell Reports</i> , 2013, 5, 637-645.	2.9	289
123	Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer. <i>Cell</i> , 2013, 155, 552-566.	13.5	151
124	VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. <i>Molecular Therapy</i> , 2013, 21, 1014-1023.	3.7	34
125	A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. <i>Nature Communications</i> , 2013, 4, 2035.	5.8	252
126	Inhibition of Multiple Pathogenic Pathways by Histone Deacetylase Inhibitor SAHA in a Corneal Alkali-Burn Injury Model. <i>Molecular Pharmaceutics</i> , 2013, 10, 307-318.	2.3	28

#	ARTICLE	IF	CITATIONS
127	RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas. <i>Cancer Discovery</i> , 2013, 3, 444-457.	7.7	104
128	PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1190-1201.	1.9	63
129	BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 992-1001.	1.9	90
130	Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulinitis and Restoring Islet Function. <i>Diabetes</i> , 2013, 62, 2870-2878.	0.3	35
131	Mouse Models of Pancreatic Cancer. , 2013, , 57-91.		1
132	Loss of SPARC in bladder cancer enhances carcinogenesis and progression. <i>Journal of Clinical Investigation</i> , 2013, 123, 751-66.	3.9	69
133	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 1732-1740.	3.9	166
134	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 3183-3183.	3.9	7
135	Enhanced Heme Function and Mitochondrial Respiration Promote the Progression of Lung Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e63402.	1.1	92
136	Vascular Endothelial Growth Factor Receptor-2 Promotes the Development of the Lymphatic Vasculature. <i>PLoS ONE</i> , 2013, 8, e74686.	1.1	61
137	Stromal Platelet-Derived Growth Factor Receptor α (PDGFR α) Provides a Therapeutic Target Independent of Tumor Cell PDGFR α Expression in Lung Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2473-2482.	1.9	34
138	Lack of "immunological fitness" during fasting in metabolically challenged animals. <i>Journal of Lipid Research</i> , 2012, 53, 1254-1267.	2.0	37
139	Dichotomous effects of VEGF-A on adipose tissue dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5874-5879.	3.3	337
140	Epithelial "mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. <i>Carcinogenesis</i> , 2012, 33, 1639-1646.	1.3	24
141	TGF- β 2 and α 6 Integrin Act in a Common Pathway to Suppress Pancreatic Cancer Progression. <i>Cancer Research</i> , 2012, 72, 4840-4845.	0.4	82
142	Anti-VEGF Therapy Revived by c-Met Inhibition, but Is c-Met the Answer?. <i>Cancer Discovery</i> , 2012, 2, 211-213.	7.7	3
143	Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5031-5042.	3.2	54
144	Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGF β 2 Activation. <i>PLoS ONE</i> , 2012, 7, e31384.	1.1	69

#	ARTICLE	IF	CITATIONS
145	Accumulation of Pro-Cancer Cytokines in the Plasma Fraction of Stored Packed Red Cells. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 460-468.	0.9	33
146	Effect of 2G8, a TGF-beta-R2 inhibitor, on TGF-beta signaling and migration in an immunocompetent pancreatic cancer model.. <i>Journal of Clinical Oncology</i> , 2012, 30, 230-230.	0.8	0
147	Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2012, 30, 234-234.	0.8	0
148	Rgs16 is a pancreatic reporter of chronic hyperglycemia in diabetes. <i>FASEB Journal</i> , 2012, 26, 759.6.	0.2	0
149	Ligand induced activation of VEGFR during angiogenesis. <i>FASEB Journal</i> , 2012, 26, 971.2.	0.2	0
150	Stromal and antitumor effects of BIBF 1120 (nintedanib) in a preclinical lung cancer model.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13563-e13563.	0.8	0
151	TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation. <i>Molecular Cell</i> , 2011, 41, 458-470.	4.5	187
152	Phosphorylation of Akt and ERK1/2 Is Required for VEGF-A/VEGFR2-Induced Proliferation and Migration of Lymphatic Endothelium. <i>PLoS ONE</i> , 2011, 6, e28947.	1.1	79
153	Update on vascular disrupting agents for cancer therapy. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 403-413.	0.2	1
154	The regulatory function of SPARC in vascular biology. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3165-3173.	2.4	81
155	SMAC Mimetic (JP1201) Sensitizes Non- Small Cell Lung Cancers to Multiple Chemotherapy Agents in an IAP-Dependent but TNF-Independent Manner. <i>Cancer Research</i> , 2011, 71, 7640-7648.	0.4	55
156	Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. <i>Cancer Biology and Therapy</i> , 2011, 12, 617-628.	1.5	29
157	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of Î²-Lapachone for Pancreatic Cancer Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 275-285.	3.2	96
158	SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-Î²1 activity. <i>Journal of Cell Biology</i> , 2011, 193, 1305-1319.	2.3	64
159	SPARC Promotes Cathepsin B-Mediated Melanoma Invasiveness through a Collagen I/Î²2Î²1 Integrin Axis. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2438-2447.	0.3	61
160	SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H841-H847.	1.5	66
161	SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-b1 activity. <i>Journal of Experimental Medicine</i> , 2011, 208, i22-i22.	4.2	0
162	Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. <i>Anticancer Research</i> , 2011, 31, 843-7.	0.5	5

#	ARTICLE	IF	CITATIONS
163	The VEGF family in cancer and antibody-based strategies for their inhibition. <i>MAbs</i> , 2010, 2, 165-175.	2.6	144
164	GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. <i>BMC Cancer</i> , 2010, 10, 397.	1.1	36
165	Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice. <i>Cancer</i> , 2010, 116, 3862-3874.	2.0	22
166	VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer. <i>Cancers</i> , 2010, 2, 970-988.	1.7	20
167	r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction. <i>PLoS ONE</i> , 2010, 5, e12031.	1.1	38
168	Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. <i>Experimental Biology and Medicine</i> , 2010, 235, 3-9.	1.1	39
169	Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. <i>Experimental Biology and Medicine</i> , 2010, 235, 263-270.	1.1	37
170	Clonal Analysis Reveals a Common Progenitor for Endothelial, Myeloid, and Lymphoid Precursors in Umbilical Cord Blood. <i>Circulation Research</i> , 2010, 107, 1460-1469.	2.0	24
171	Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 57-72.	1.2	101
172	Loss of fibulin-5 binding to $\alpha 1$ integrins inhibits tumor growth by increasing the level of ROS. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 333-342.	1.2	56
173	Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3170-3180.	0.4	24
174	Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer. <i>Cancer Research</i> , 2010, 70, 2852-2861.	0.4	99
175	Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 567-580.	1.2	48
176	MRI Detection of VEGFR2 <i>in Vivo</i> Using a Low Molecular Weight Peptoid ⁸ (Gd)-Dendron for Targeting. <i>Journal of the American Chemical Society</i> , 2010, 132, 12829-12831.	6.6	48
177	Non-nuclear estrogen receptor β signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2319-2330.	3.9	217
178	The Function of SPARC in Tumor Cell Biology: SPARC as a Modulator of Cell-Extracellular Matrix Interaction. , 2010, , 171-189.		0
179	Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer. <i>PLoS ONE</i> , 2009, 4, e7669.	1.1	168
180	Hypoxia-Inducible Factor 1β Induces Fibrosis and Insulin Resistance in White Adipose Tissue. <i>Molecular and Cellular Biology</i> , 2009, 29, 4467-4483.	1.1	720

#	ARTICLE	IF	CITATIONS
181	Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1761-1771.	1.9	165
182	K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways. <i>Molecular Cancer Research</i> , 2009, 7, 799-808.	1.5	72
183	Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. <i>Journal of Cell Communication and Signaling</i> , 2009, 3, 337-347.	1.8	131
184	SPARC: a matricellular regulator of tumorigenesis. <i>Journal of Cell Communication and Signaling</i> , 2009, 3, 255-273.	1.8	147
185	Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. <i>Nature Medicine</i> , 2009, 15, 1023-1030.	15.2	328
186	Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 180.e1-180.e7.	0.7	16
187	The Acellular Fraction of Stored Platelets Promotes Tumor Cell Invasion. <i>Journal of Surgical Research</i> , 2009, 153, 132-137.	0.8	24
188	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e7464.	1.1	205
189	A peptoid antagonist of VEGF Receptor 2 recognizes a "hotspot"™ in the extracellular domain distinct from the hormone-binding site. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6338-6343.	1.4	26
190	The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5892-5894.	1.0	33
191	The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. <i>BMC Cancer</i> , 2008, 8, 352.	1.1	58
192	147. The Acellular Fraction of Stored Platelets Promotes Cancer Invasion. <i>Journal of Surgical Research</i> , 2008, 144, 241-242.	0.8	1
193	A Peptoid "Antibody Surrogate" That Antagonizes VEGF Receptor 2 Activity. <i>Journal of the American Chemical Society</i> , 2008, 130, 5744-5752.	6.6	220
194	Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice. <i>Cancer Research</i> , 2008, 68, 4340-4346.	0.4	175
195	Forced Expression of MMP9 Rescues the Loss of Angiogenesis and Abrogates Metastasis of Pancreatic Tumors Triggered by the Absence of Host SPARC. <i>Experimental Biology and Medicine</i> , 2008, 233, 860-873.	1.1	62
196	Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis. <i>Cancer Research</i> , 2008, 68, 9050-9059.	0.4	174
197	Semaphorin 3B Inhibits the Phosphatidylinositol 3-Kinase/Akt Pathway through Neuropilin-1 in Lung and Breast Cancer Cells. <i>Cancer Research</i> , 2008, 68, 8295-8303.	0.4	71
198	Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature. <i>Clinical Cancer Research</i> , 2007, 13, 323-330.	3.2	256

#	ARTICLE	IF	CITATIONS
199	Malignant Progression and Blockade of Angiogenesis in a Murine Transgenic Model of Neuroblastoma. <i>Cancer Research</i> , 2007, 67, 9435-9442.	0.4	58
200	Angiogenic Role of LYVE-1-Positive Macrophages in Adipose Tissue. <i>Circulation Research</i> , 2007, 100, e47-57.	2.0	253
201	The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. <i>International Journal of Cancer</i> , 2007, 120, 753-760.	2.3	44
202	Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. <i>International Journal of Cancer</i> , 2007, 121, 2181-2191.	2.3	88
203	Progesterin-Dependent Progression of Human Breast Tumor Xenografts: A Novel Model for Evaluating Antitumor Therapeutics. <i>Cancer Research</i> , 2007, 67, 9929-9936.	0.4	75
204	Targeting Inside-Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer. , 2006, , 179-194.		1
205	Incorporation of Bone Marrow-derived Flk-1-expressing CD34+ Cells in the Endothelium of Tumor Vessels in the Mouse Brain. <i>Neurosurgery</i> , 2006, 59, 374-382.	0.6	53
206	Selective Blockade of Vascular Endothelial Growth Factor Receptor 2 With an Antibody Against Tumor-Derived Vascular Endothelial Growth Factor Controls the Growth of Human Pancreatic Adenocarcinoma Xenografts. <i>Annals of Surgical Oncology</i> , 2006, 13, 1145-1155.	0.7	28
207	Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. <i>International Journal of Cancer</i> , 2006, 118, 2639-2643.	2.3	70
208	Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. <i>Endocrine-Related Cancer</i> , 2006, 13, 905-919.	1.6	125
209	Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. <i>Journal of Clinical Investigation</i> , 2006, 116, 422-429.	3.9	84
210	Targeting vascular endothelium with avidin microbubbles. <i>Ultrasound in Medicine and Biology</i> , 2005, 31, 1279-1283.	0.7	89
211	Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. <i>Journal of the American College of Surgeons</i> , 2005, 200, 371-377.	0.2	74
212	Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras-Directed Therapy. <i>Molecular Cancer Research</i> , 2005, 3, 413-423.	1.5	173
213	SPARC-thrombospondin-2-double-null Mice Exhibit Enhanced Cutaneous Wound Healing and Increased Fibrovascular Invasion of Subcutaneous Polyvinyl Alcohol Sponges. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 571-581.	1.3	29
214	Functional Analysis of the Matricellular Protein SPARC with Novel Monoclonal Antibodies. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 723-733.	1.3	40
215	Expression and Characterization of Murine Hevin (SC1), a Member of the SPARC Family of Matricellular Proteins. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 735-748.	1.3	55
216	Age-Related Changes in Vascular Endothelial Growth Factor Dependency and Angiopoietin-1-Induced Plasticity of Adult Blood Vessels. <i>Circulation Research</i> , 2004, 94, 984-992.	2.0	111

#	ARTICLE	IF	CITATIONS
217	Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6993-7000.	3.2	74
218	SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 915-925.	1.2	94
219	SPARC-like 1 Regulates the Terminal Phase of Radial Glia-Guided Migration in the Cerebral Cortex. <i>Neuron</i> , 2004, 41, 57-69.	3.8	103
220	Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. <i>Molecular Cancer Research</i> , 2004, 2, 215-24.	1.5	68
221	Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis. <i>Molecular Cancer Research</i> , 2004, 2, 215-224.	1.5	134
222	Role of VEGF-A in Vascularization of Pancreatic Islets. <i>Current Biology</i> , 2003, 13, 1070-1074.	1.8	351
223	Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2003, 90, 492-501.	1.2	14
224	Compromised Production of Extracellular Matrix in Mice Lacking Secreted Protein, Acidic and Rich in Cysteine (SPARC) Leads to a Reduced Foreign Body Reaction to Implanted Biomaterials. <i>American Journal of Pathology</i> , 2003, 162, 627-635.	1.9	63
225	The matricellular protein SPARC is expressed in human trabecular meshwork. <i>Experimental Eye Research</i> , 2003, 77, 601-607.	1.2	54
226	Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. <i>Journal of Clinical Investigation</i> , 2003, 111, 487-495.	3.9	170
227	Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. <i>Cancer Research</i> , 2003, 63, 5376-80.	0.4	146
228	Strategies for vascular targeting in tumors. <i>International Journal of Cancer</i> , 2002, 100, 123-130.	2.3	53
229	Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. <i>Oncogene</i> , 2002, 21, 7011-7026.	2.6	305
230	SPARC, a matricellular protein: at the crossroads of cell-matrix communication. <i>Matrix Biology</i> , 2001, 19, 815-827.	1.5	491
231	Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. <i>Wound Repair and Regeneration</i> , 2001, 9, 522-530.	1.5	56
232	The angiogenic vascular endothelial growth factor/flk-1 (KDR) receptor pathway in patients with endometrial carcinoma. <i>Cancer</i> , 2001, 92, 2569-2577.	2.0	73
233	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. <i>Nature Cell Biology</i> , 2000, 2, 737-744.	4.6	2,487
234	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 313-319.	1.7	8

#	ARTICLE	IF	CITATIONS
235	Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2 (FLK-1, KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 545-555.	1.3	106
236	SPARC, a matricellular protein: at the crossroads of cellâ€matrix. <i>Matrix Biology</i> , 2000, 19, 569-580.	1.5	304
237	Expression of Soluble VEGF Receptor 2 and Characterization of Its Binding by Surface Plasmon Resonance. <i>Biochemical and Biophysical Research Communications</i> , 1998, 252, 643-648.	1.0	29
238	Mesothelial Cell-Derived Antigen-Presenting Cancer-Associated Fibroblasts Induce Expansion of Regulatory T Cells in Pancreatic Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3